Wet AMD 1 Symposium

Related

• 

  Two-Year Results From the Subretinal RGX-314 Gene Therapy Phase 1/2a Study for the Treatment of Neovascular AMD

  Robert L. Avery, MD

  Updates from the Field

  2021

• 

  Assessing Supplemental Injection Use Across Groups in the Phase 2 DAVIO 2 Trial of EYP-1901 vs Aflibercept in Wet Age-Related Macular Degeneration

  Veeral S. Sheth, MD, MBA, FASRS, FACS

  Annual Meeting Talks

  2024

• 

  Retinal Vascular Disease Take-Home Panel

  Neil M. Bressler, MD

  Annual Meeting Talks

  2019